GreenLight Biosciences Raises $17 Million to Scale Up COVID-19 Vaccine Manufacturing

Boston-based GreenLight Biosciences closed an oversubscribed $17 million “special purpose funding round” in order to expand its scalable mRNA manufacturing capability for its mRNA COVID-19 vaccine. The goal is to be able to produce billions of doses.